Green tea extract / EGCG (research-only chemoprevention candidate — NOT standard-of-care)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-GREEN-TEA-EXTRACT-RESEARCH |
|---|---|
| Type | Drug |
| Aliases | Camellia sinensis polyphenolsEpigallocatechin gallate (EGCG)Green tea catechinsGreen tea extract / EGCG researchPolyphenon E (standardized formulation)various OTC supplements — Polyphenon E, Veregen (topical, FDA-approved for genital warts)Екстракт зеленого чаю / EGCG (дослідницький кандидат — НЕ стандарт) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-PROSTATE-2025 SRC-WCRF-AICR-CUP-2018 |
Drug Facts
| Class | Polyphenol catechin mixture from Camellia sinensis — dietary supplement |
|---|---|
| Mechanism | Standardized catechin mixture from green tea leaves, dominated by (-)-epigallocatechin-3-gallate (EGCG, ~50-70% of total catechins). Preclinical mechanisms include inhibition of receptor tyrosine kinases (EGFR, VEGFR), suppression of NF-κB, modulation of mTOR and AMPK, DNA-methyltransferase inhibition (epigenetic), induction of apoptosis, and inhibition of angiogenesis in cancer cell lines. Cancer-prevention rationale: ecological data (East Asian green-tea consumption) correlated with lower incidence of multiple cancers; preclinical signal in skin, breast, prostate, oral, and colorectal models. CLINICAL TRANSLATION IS MIXED: prostate-cancer prevention RCT in HGPIN (Bettuzzi 2006, n=60 — 90% reduction in 1-year cancer detection with 600 mg/d catechins) was small and was NOT replicated in larger Bettuzzi 2008 / Kumar 2015 (Polyphenon E in HGPIN/ASAP, n=97, FUTURE trial null). EGCG hepatot... |
| Typical dosing | RESEARCH-ONLY context — NO accepted clinical-use dose for cancer chemoprevention: Polyphenon E (standardized EGCG-rich extract): 200-600 mg EGCG equivalent daily in prevention trials (HGPIN, oral premalignancy). EFSA 2018 acceptable daily intake from green-tea-extract supplements: ≤800 mg EGCG/day; above this threshold rising hepatotoxicity risk. Dietary green-tea consumption (3-5 cups/day) provides ~150-250 mg EGCG and is regarded as safe; supplement-based high-dose EGCG is the safety concern. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 chemoprevention-workstream authoring (batch 2); pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. GREEN-TEA EXTRACT / EGCG IS NOT STANDARD-OF-CARE CHEMOPREVENTION (research- only context). Clinical data are mixed and inconsistent: - Bettuzzi 2006 (n=60, HGPIN, 1 year): ~90% reduction in prostate- cancer detection — promising but small. - Kumar 2015 / FUTURE trial (n=97, HGPIN/ASAP, 1 year, Polyphenon E): NULL for prostate-cancer detection. - Oral-premalignancy trials (Tsao 2009, Schwartz 2014): small, mixed surrogate-endpoint results. EFSA 2018 — daily intake of EGCG from green-tea-extract supplements should not exceed 800 mg/day due to rising hepatotoxicity signal at higher doses, particularly on an empty stomach. Dietary green-tea consumption (3-5 cups/d) is generally safe and is the preferred exposure mode in WCRF-AICR recommendations. NCCN / USPSTF / WCRF / ASCO — no recommendation for green-tea-extract supplementation for cancer prevention. EXPLICIT CAUTION: avoid green-tea extract in patients on bortezomib (multiple myeloma) — EGCG abolishes bortezomib efficacy. ENGINE MUST NOT recommend green-tea extract for cancer prevention; entity exists for cat...
Used By
No reverse references found in the YAML corpus.